Abstract
This study used the Korean National Health Insurance (NHI) claims database from 2011 to 2017 to estimate the incidence and the incidence-based cost of cervical cancer and carcinoma in situ of cervix uteri (CIS) in Korea. The primary outcome was the direct medical cost per patient not diagnosed with cervical cancer (C53) or CIS (D06) 2 years prior to the index date in the first year after diagnosis. A regression analysis was conducted to adjust for relevant covariates. The incidence of cervical cancer tended to decrease from 2013 to 2016, while that of CIS increased. In particular, the incidence rate of CIS in women in their 20 s and 30 s increased by 56.8% and 28.4%, respectively, from 2013 to 2016. The incidence-based cost of cervical cancer and CIS was USD 13,058 and USD 2695 in 2016, respectively, which increased from 2013. Multivariate regression analysis suggested that age was the most influential variable of the cost in both patient groups, and the cost was highest in those aged over 60, i.e., the medical cost was significantly lower in younger women than their older counterparts. These findings suggest that targeting younger women in cervical cancer prevention is a reasonable option from both economic and public health perspectives.
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health
Reference45 articles.
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
2. Annual Report of Cancer Statistics in Korea in 2016File:///C:/Users/MDPI/AppData/Local/Temp/Annual_report_of_cancer_statistics_in_Korea_in_2016.pdf
3. Chapter 7: Achievements and limitations of cervical cytology screening
4. Epidemiology of Cervical Cancer
5. Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine;Braaten;Rev. Obstet. Gynecol.,2008
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献